Skip to main content
SpringerLink
Log in

iGlarLixi for type 2 diabetes: a systematic review and meta-analysis

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Objectives

To assess the efficacy and tolerability of iGlarLixi—a novel, fixed-ratio, soluble combination of insulin glargine and lixisenatide—for the treatment of type 2 diabetes (T2D).

Methods

The PubMed, Embase, Cochrane Library and ClinicalTrials.gov databases were searched from inception to November 15, 2023 to identify randomized controlled trials (RCTs) comparing iGlarLixi with a placebo or any other antidiabetic agent in adults with T2D. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated to evaluate the outcomes.

Results

A total of 10 trials enrolling 6071 T2D patients were included. Compared with placebos or other antidiabetic agents, iGlarLixi exerted beneficial effects on changes in HbA1c, the percentage of patients who achieved an HbA1c < 7%, the percentage of patients who achieved an HbA1c < 6.5%, the percentage of patients who achieved an HbA1c < 7.0% without weight gain and/or without severe or blood glucose-confirmed hypoglycemic episodes, changes in fasting plasma glucose, and changes in self-measured plasma glucose. Regarding safety, iGlarLixi did not increase the incidence of severe hypoglycemia or serious adverse events but did increase the incidence of gastrointestinal adverse events, symptomatic hypoglycemia, and adverse events (e.g., nausea, vomiting, diarrhea).

Conclusions

iGlarLixi showed improved efficacy and safety in patients with T2D. Additional large, multicenter RCTs are warranted to obtain deeper insights into the efficacy and safety of iGlarLixi, thereby providing guidance for clinical treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.

  2. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.

  3. M.J. Davies, D.A. D’Alessio, J. Fradkin et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12), 2461–2498 (2018)

    Article  PubMed  Google Scholar 

  4. N.A. ElSayed, G. Aleppo, V.R. Aroda et al. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care 46(Suppl 1), S140–S157 (2023)

    Article  CAS  PubMed  Google Scholar 

  5. Chinese Diabetes Society, Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin. J. Diabetes Mellitus 13(4), 315–409 (2020)

    Google Scholar 

  6. H. Kaneto, A. Takami, R. Spranger et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial. Diabetes Obes. Metab. 22(Suppl 4), 3–13 (2020)

    Article  CAS  PubMed  Google Scholar 

  7. Y. Terauchi, T. Nakama, R. Spranger et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial. Diabetes Obes. Metab. 22(Suppl 4), 14–23 (2020)

    Article  CAS  PubMed  Google Scholar 

  8. J. Rosenstock, M. Diamant, V.R. Aroda et al. Efficacy and safety of lixilan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: The LixiLan proof-of-concept randomized trial. Diabetes Care 39(9), 1579–1586 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. L. Blonde, J. Rosenstock, S. Del Prato et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: The LixiLan-G randomized clinical trial. Diabetes Care 42(11), 2108–2116 (2019)

    Article  CAS  PubMed  Google Scholar 

  10. V.R. Aroda, J. Rosenstock, C. Wysham et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. Diabetes Care 39(11), 1972–1980 (2016)

    Article  CAS  PubMed  Google Scholar 

  11. P. Home, L. Blonde, S. Kalra et al. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. Diabetes Obes. Metab. 22(11), 2179–2188 (2020)

    Article  CAS  PubMed  Google Scholar 

  12. X. Yuan, X. Guo, J. Zhang et al. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial. Diabetes Obes. Metab. 24(11), 2182–2191 (2022)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. W. Yang, X. Dong, Q. Li et al. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Diabetes Obes. Metab. 24(8), 1522–1533 (2022)

    Article  CAS  PubMed  Google Scholar 

  14. J. Rosenstock, R. Emral, L. Sauque-Reyna et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care 44(10), 2361–2370 (2021)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. H.S. Bajaj, L. Chu, N. Bansal et al. Randomized comparison of initiating the fixed-ratio combination of iGlarLixi or biosimilar insulin glargine together with gliclazide in participants of south asian origin with type 2 diabetes: VARIATION 2 SA trial. Can J. Diabetes 46(5), 495–502 (2022)

    Article  PubMed  Google Scholar 

  16. D. Moher, A. Liberati, J. Tetzlaff et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  17. A. Liberati, D.G. Altman, J. Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  18. S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol 5, 13 (2005)

    Article  PubMed  PubMed Central  Google Scholar 

  19. X. Wan, W. Wang, J. Liu et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol 14, 135 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  20. Higgins JPT, Thomas J., Chandler J., et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.

  21. J. Rosenstock, R. Aronson, G. Grunberger et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 39(11), 2026–2035 (2016)

    Article  CAS  PubMed  Google Scholar 

  22. M.J. Lage, K.S. Boye, The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database. Curr Med Res Opin 36(9), 1441–1447 (2020)

    Article  CAS  PubMed  Google Scholar 

  23. R.R. Holman, S.K. Paul, M.A. Bethel et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359(15), 1577–1589 (2008)

    Article  CAS  PubMed  Google Scholar 

  24. D.M. Nathan, M. Bayless, P. Cleary et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 62(12), 3976–3986 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. R.J. McCrimmon, M. Lamotte, M. Ramos et al. Cost-effectiveness of iGlarLixi Versus iDegLira in type 2 diabetes mellitus inadequately controlled by GLP-1 receptor agonists and oral antihyperglycemic therapy. Diabetes Ther. 12(12), 3231–3241 (2021)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. K.M. Pantalone, C. Heller, R. Lajara et al. Initiation of iGlarLixi versus basal-bolus insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study. Diabetes Spectr 36(3), 253–263 (2023)

    Article  PubMed  PubMed Central  Google Scholar 

  27. S. Edelman, D. Cassarino, D. Kayne et al. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J. Manag. Care Spec. Pharm. 28(9), 958–968 (2022)

    PubMed  Google Scholar 

  28. M. Munshi, R. Ritzel, E.B. Jude et al. Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials. Diabetes Obes. Metab. 26(3), 851–859 (2024)

    Article  CAS  PubMed  Google Scholar 

Download references

Author contributions

Y.L. and X.W. conceived the study and prepared the first draft of the report. Y.L., C.L., and X.L. conducted the literature search, literature selection and data extraction. J.Y., Y.Z., F.L., and X.W. contributed to the statistical analyses and data interpretation and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Hebei Provincial Medical Science Research Project Plan in 2024 (No. 20241798).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, China

    Yang Liu, Congxin Li, Xuejing Li, Jie Yang, Yingying Zheng, Fan Li & Xianying Wang

Authors
  1. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Congxin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuejing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yingying Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xianying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xianying Wang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Li, C., Li, X. et al. iGlarLixi for type 2 diabetes: a systematic review and meta-analysis. Endocrine (2024). https://doi.org/10.1007/s12020-024-03868-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12020-024-03868-3

Keywords

Search

Navigation